You are here:

March 2014

19 March 2014

Brain volume loss and progression of the condition were both slowed and quality of life was improved

140 people with secondary progressive multiple sclerosis took either high dose simvastatin (80mg/day) or placebo in this two year, phase II clinical trial. MRI scans measured brain volume during the course of the study, disability was measured using the EDSS scale and participants completed questionnaires to measure the impact of MS on day-to-day living. Simvastatin was well tolerated by the participants.